Cure My Disease

Don't miss your cure!

 Log in / Sign up

Is thicker blood a hidden player in ARDS?

NCT ID NCT07823296

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

ARDS is a severe lung condition that damages the tiny air sacs and blood vessels in the lungs, leading to low oxygen and unstable circulation. Researchers at Hospices Civils de Lyon are measuring blood viscosity, or how thick and resistant to flow the blood is, in ICU patients with ARDS and comparing them with patients admitted for other reasons. They draw small blood samples over several days and use a viscometer to test how the blood flows under different forces. The goal is to see whether higher viscosity is linked to worse breathing or circulation during ARDS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If blood viscosity turns out to be higher in ARDS and tracks with breathing or circulation problems, it could point toward new ways to monitor or treat the condition.
What could go wrong
This is a small observational study of 46 people in one hospital system. It can show a link between viscosity and ARDS but cannot prove that viscosity causes harm or that changing it helps patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Intensive care patients treated at the Croix Rousse Hospital

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Case Group Inclusion Criteria: * Age ≥ 18 ans * Moderate-to-severe ARDS according to the global definition: * with PaO₂/FiO₂ ≤ 200 mmHg (based on arterial blood gas analysis in patients receiving invasive or non-invasive mechanical ventilation or high-flow nasal oxygen therapy). * Participation agreement obtained (either from the patient themselves or from a relative) Exclusion Criteria: * ARDS that has been present for more than 72 hours * Terminally ill patient with death expected within 24 hours * Patient who has received a blood transfusion within the past month * Patient with a known hematologic malignancy (lymphoma; myeloma; acute or chronic leukemia) * Patient with a known hemoglobinopathy. * Hemorrhagic shock * Hemoglobin \< 70 g/dL Control group Inclusion Criteria: * Age ≥ 18 ans * Participation agreement obtained (either from the patient themselves or from a relative) Exclusion Criteria: * Presence of ARDS according to the global definition * P/F \< 300 mmHg * Presence of sepsis defined by an infection and a SOFA score delta ≥ 2. * Terminally ill patient with death expected within 24 hours * Patient who has received a blood transfusion within the past month * Patient with a known hematologic malignancy (lymphoma; myeloma; acute or chronic leukemia) * Patient with a known hemoglobinopathy. * Hemorrhagic shock * Hemoglobin \< 70 g/dL

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital de la Croix-Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.